Avalanche Biotechnologies to Present at Upcoming Investor Conferences
Cowen and Company35th Annual Health Care Conferenceon Wednesday, March 4, 2015at 9:20 a.m. ESTin Boston.
Barclays Global Healthcare Conferenceon Tuesday, March 10, 2015at 2:50 p.m. EDTin Miami, FL.
- Alliance for Regenerative Medicine’s 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 2:25 p.m. EDT in New York.
Live webcasts of the Cowen and Company and Barclays presentations will be accessible under Events & Presentations in the Investors section of Avalanche's website. Avalanche will maintain an archived replay of the webcasts on its website for two weeks after each conference.
About Avalanche Biotechnologies, Inc.
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche's lead product, AVA-101, is currently under development in a Phase 2a trial for wet age-related macular degeneration. Avalanche's Ocular BioFactory™ platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information, please visit www.avalanchebiotech.com.
CONTACT: Media and Investor Contact